The STAND4Kids pediatric network provides support to research sites throughout the lifecycle of each adopted trial, in alignment with the Sponsor/CRO who is responsible for the trial execution in line with legislation and Good Clinical Practice. As a facilitator and mediator working with sites, the STAND4Kids team works with researchers and study teams to solve and overcome challenges that may arise during feasibility, country and site setup and study implementation.
Our trial portfolio, which has been increasing, includes the conect4children Proof-of-Viability study on pediatric Ashma (Study CQMF149G2301). This study sponsored by Novartis aims to evaluate the efficacy and safety of the QMF149 study drug (indacaterol (acetate form) / mometasone furoate) in children with aged between 6 years and less than 12 years with asthma. The researchers want to see if the study drug is works as well or better than budesonide (currently used to prevent asthma attacks) at improving lung function (by determining FEV1).
The study will select potential participants until September 2025.
You can find more information about this study on: https://pt-pt.qmf149asthmastudy.com/
(Contents aimed at residents of Portugal)
